• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Yellow Fever - Pipeline Review, H2 2012 Product Image

Yellow Fever - Pipeline Review, H2 2012

  • ID: 2244971
  • September 2012
  • 39 pages
  • Global Markets Direct

Yellow Fever – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Yellow Fever - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Yellow Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Yellow Fever. Yellow Fever - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Yellow Fever.
- A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Yellow Fever Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Yellow Fever 7
Yellow Fever Therapeutics under Development by Companies 9
Yellow Fever Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Yellow Fever Therapeutics – Products under Development by Companies 14
Yellow Fever Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Yellow Fever Therapeutics Development 16
Alfacell Corporation 16
Crucell N.V. 17
iBio, Inc. 18
Xcellerex, Inc. 19
Yellow Fever – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
Flavimun - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Flavimun - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
XRX-001 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Yellow Fever Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
squalamine lactate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
rAmphinase 2 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Yellow Fever Therapeutics – Drug Profile Updates 33
Yellow Fever Therapeutics - Dormant Products 34
Yellow Fever – Product Development Milestones 35
Featured News & Press Releases 35
Sep 19, 2011: Georgetown University Medical Center Researcher Proves Shark Compound To Be Potential Drug To Treat Human Viruses 35
Apr 07, 2011: Xcellerex Announces Positive Results From Phase I Clinical Trial Of XRX-001 36
Aug 10, 2010: New Hope in Finding Cure for Yellow Fever 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Number of Products Under Development for Yellow Fever, H2 2012 7
Products under Development for Yellow Fever – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Alfacell Corporation, H2 2012 16
Crucell N.V., H2 2012 17
iBio, Inc., H2 2012 18
Xcellerex, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Yellow Fever Therapeutics – Drug Profile Updates 33
Yellow Fever Therapeutics – Dormant Products 34

List of Figures
Number of Products under Development for Yellow Fever, H2 2012 7
Products under Development for Yellow Fever – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos